Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$94.22
+3.3%
$93.96
$79.52
$124.00
$23.79B1.331.06 million shs698,230 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$170.10
+0.9%
$151.99
$122.14
$171.43
$17.11B0.391.18 million shs902,041 shs
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$62.32
+0.5%
$59.36
$49.90
$73.18
$25.84B0.9582,786 shs27,813 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shsN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$70.84
-0.2%
$52.95
$43.19
$72.16
$11.10B1.373.15 million shs11.06 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.36%-4.93%+7.00%-14.52%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+6.46%+6.46%+30.92%+34.36%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.00%+4.17%+7.23%+3.78%-14.27%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%+22.54%+37.38%+36.43%+36.96%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$94.22
+3.3%
$93.96
$79.52
$124.00
$23.79B1.331.06 million shs698,230 shs
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$170.10
+0.9%
$151.99
$122.14
$171.43
$17.11B0.391.18 million shs902,041 shs
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$62.32
+0.5%
$59.36
$49.90
$73.18
$25.84B0.9582,786 shs27,813 shs
Seagen Inc. stock logo
SGEN
Seagen
$228.74
$228.74
$123.77
$228.96
$42.93B0.321.48 million shsN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$70.84
-0.2%
$52.95
$43.19
$72.16
$11.10B1.373.15 million shs11.06 million shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.00%+0.36%-4.93%+7.00%-14.52%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
0.00%+6.46%+6.46%+30.92%+34.36%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.00%+4.17%+7.23%+3.78%-14.27%
Seagen Inc. stock logo
SGEN
Seagen
0.00%0.00%0.00%0.00%0.00%
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.00%+22.54%+37.38%+36.43%+36.96%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
2.74
Moderate Buy$129.5638.50% Upside
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.96
Moderate Buy$187.5210.96% Upside
Novozymes A/S stock logo
NVZMY
Novozymes A/S
3.33
BuyN/AN/A
Seagen Inc. stock logo
SGEN
Seagen
0.00
N/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
2.44
Hold$68.29-3.64% Downside

Current Analyst Ratings Breakdown

Latest SGEN, NVZMY, NBIX, BNTX, and TECH Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/26/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeBuyNeutral$70.00 ➝ $73.00
6/26/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Set Price TargetOverweightEqual Weight$68.00 ➝ $73.00
6/26/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeBuyHold$73.00
6/26/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeStrong-BuyHold
6/26/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Boost Price TargetNeutral$49.00 ➝ $73.00
6/25/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeOutperformMarket Perform
6/25/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Set Price Target$73.00
6/25/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
DowngradeStrong-BuyHold
6/25/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
UpgradeHoldStrong-Buy
6/24/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
UpgradeBuy (B-)Buy (B)
6/23/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
Reiterated RatingBuy
(Data available from 6/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
$3.25B7.29$1.37 per share68.32$96.59 per share0.97
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.86B5.94$5.03 per share33.62$32.63 per share5.18
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$4.70B5.49$1.68 per share36.97$26.23 per share2.37
Seagen Inc. stock logo
SGEN
Seagen
$2.30B18.66N/AN/A$15.10 per share15.15
Bio-Techne Corp stock logo
TECH
Bio-Techne
$1.21B9.16$2.44 per share29.04$12.24 per share5.79
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$1.29B-$5.88N/AN/AN/A-44.39%-5.30%-4.62%8/4/2026 (Estimated)
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$478.60M$6.4926.0916.980.6721.55%19.79%13.82%7/29/2026 (Estimated)
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$660.28M$1.4842.0524.031.1614.22%6.52%4.30%8/20/2026 (Estimated)
Seagen Inc. stock logo
SGEN
Seagen
-$610.31M-$4.01N/AN/AN/A-32.61%-28.06%-20.92%N/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$73.40M$0.69102.7340.266.889.05%13.57%10.66%8/5/2026 (Estimated)

Latest SGEN, NVZMY, NBIX, BNTX, and TECH Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/6/2026Q3 2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.55$0.53-$0.02$0.32$316.11 million$311.42 million
5/5/2026Q1 2026
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$0.8160$0.51-$0.3060$0.50$1.32 billion$1.31 billion
5/4/2026Q1 2026
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
-$2.52-$2.2570+$0.2630-$2.43$207.42 million$136.71 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
N/AN/AN/AN/AN/A
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
Novozymes A/S stock logo
NVZMY
Novozymes A/S
$0.811.30%N/A54.73%N/A
Seagen Inc. stock logo
SGEN
Seagen
N/AN/AN/AN/AN/A
Bio-Techne Corp stock logo
TECH
Bio-Techne
$0.320.45%N/A46.38%N/A

Latest SGEN, NVZMY, NBIX, BNTX, and TECH Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/6/2026
Bio-Techne Corp stock logo
TECH
Bio-Techne
quarterly$0.080.72%5/18/20265/18/20265/29/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
0.01
8.80
8.74
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
2.93
2.85
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.27
1.67
1.03
Seagen Inc. stock logo
SGEN
Seagen
N/A
2.67
2.12
Bio-Techne Corp stock logo
TECH
Bio-Techne
0.10
4.49
3.18

Institutional Ownership

CompanyInstitutional Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
15.52%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
0.03%
Seagen Inc. stock logo
SGEN
Seagen
84.26%
Bio-Techne Corp stock logo
TECH
Bio-Techne
98.95%

Insider Ownership

CompanyInsider Ownership
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
19.20%
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
4.60%
Novozymes A/S stock logo
NVZMY
Novozymes A/S
N/A
Seagen Inc. stock logo
SGEN
Seagen
25.90%
Bio-Techne Corp stock logo
TECH
Bio-Techne
1.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioNTech SE Sponsored ADR stock logo
BNTX
BioNTech
7,807252.88 million204.33 millionOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2,000100.55 million95.93 millionOptionable
Novozymes A/S stock logo
NVZMY
Novozymes A/S
10,933414.56 millionN/ANot Optionable
Seagen Inc. stock logo
SGEN
Seagen
3,256187.70 million139.08 millionNo Data
Bio-Techne Corp stock logo
TECH
Bio-Techne
3,100156.57 million154.53 millionOptionable

Recent News About These Companies

Bio-Techne to Be Acquired by Merck KGaA
Bio-Techne (NASDAQ:TECH) Shares Gap Up After Analyst Upgrade
The $11 Billion Reason TECH Stock Is Up Today
Bio-Techne Corporation (TECH) M&A Call Transcript
Bio-Techne (TECH) Agrees To $11.5 Billion Merck KGaA Buyout
Bio-Techne (NASDAQ:TECH) Cut to "Hold" at Leerink Partners
Top Medical Stocks To Keep An Eye On - June 25th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
BioNTech stock logo

BioNTech NASDAQ:BNTX

$94.30 +3.08 (+3.38%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$170.04 +1.52 (+0.90%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Novozymes A/S stock logo

Novozymes A/S OTCMKTS:NVZMY

$62.32 +0.31 (+0.50%)
As of 03:42 PM Eastern

Novozymes A/S produces and sells industrial enzymes, microorganisms, and probiotics in Denmark, rest of Europe, North America, Asia Pacific, the Middle East, Africa, Latin America, and internationally. The company offers protein solutions for the food and beverage industry. It also offers industrial hygiene, drain openers, hard surface, medical cleaning, septic tanks, ware washing, and professional laundry services. In addition, the company provides dishwashing, softener, microbial and medical cleaning services. Further, it provides corn, cotton, forages, peanuts, pulses, soybeans, wheat, small grains, bioyield, and biocontrol solutions; warm water species, recirculating aquaculture system; animal health and nutrition solutions; fiber modification, bleach boosting, deposit control, and starch modification solutions. Additionally, the company provides carbon capture, leather and textiles solutions; enzyme solutions, including corn and wheat separation, liquefaction, saccharification, filtration, isomerization, maltose, and specialties solutions; warm water species and recirculating aquaculture system solutions; human health solutions, comprising brain, oral, protective and immune, and gastrointestinal health solutions; ethanol, biodiesel, renewable diesel, education, wastewater, and sewage sludge, and renewable diesel solutions; agriculture and industry, biogas food waste, food waste, biocatalysis, cell culture, diagnostics, enzyme, and biogas solutions. Furthermore, it provides lipases, proteases, oxidoreductases, and carbohydrases. Novozymes A/S was founded in 1925 and is based in Bagsvaerd, Denmark.

Seagen stock logo

Seagen NASDAQ:SGEN

Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. It offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment of adult patients with advanced or metastatic urothelial cancer; and TUKYSA, an oral small molecule tyrosine kinase inhibitor for the treatment of adult patients with advanced unresectable or metastatic HER2-positive breast cancer. The company also develops TIVDAK for metastatic cervical cancer and other solid tumors; Ladiratuzumab Vedotin, an ADC targeting LIV-1 for metastatic breast cancer and solid tumors; Disitamab Vedotin, a novel HER2-targeted ADC; and SEA-TGT and SEA-CD70 for various cancer diseases. It has collaboration agreements with Takeda Pharmaceutical Company Limited; Agensys, Inc.; Genmab A/S; Merck; and RemeGen, Co. Ltd. The company was formerly known as Seattle Genetics, Inc. and changed its name to Seagen Inc. in October 2020. Seagen Inc. was incorporated in 1997 and is headquartered in Bothell, Washington. As of December 14, 2023, Seagen Inc. operates as a subsidiary of Pfizer Inc.

Bio-Techne stock logo

Bio-Techne NASDAQ:TECH

$70.88 -0.12 (-0.16%)
As of 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.